We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00206661
Recruitment Status : Terminated
First Posted : September 21, 2005
Last Update Posted : December 4, 2013
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:
The purpose of this study is to observe pediatric Crohn's Disease response to sargramostim in patients with or without steroid therapy at two possible dosage levels.

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: Sargramostim (Leukine) Phase 1 Phase 2

Detailed Description:
On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Safety, Pharmacokinetic, and Pharmacodynamic Study of Sargramostim (Leukine®) in Pediatric Patients With Active Crohn's Disease, With One-year Surveillance and Retreatment Extension
Study Start Date : December 2004
Actual Primary Completion Date : December 2006
Actual Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: Arm 1 Drug: Sargramostim (Leukine)
4 mcg sargramostim with and without corticosteroids
Other Name: BAY86-5326

Experimental: Arm 2 Drug: Sargramostim (Leukine)
6 mcg sargramostim with and without corticosteroids
Other Name: BAY86-5326

Primary Outcome Measures :
  1. Characterize the safety profile of sargramostim treatment with concomitant corticosteroid induction therapy [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Characterize the pharmacokinetic, pharmacodynamics properties of sargramostim treatment with concomitant corticosteroid induction therapy [ Time Frame: Week 0, 1, and 2 ]
  2. Evaluate the efficacy of sargramostim treatment with concomitant corticosteroids as measured by the Pediatric Crohn's Disease Activity Index (PCDAI), Physician's Global Assessment (PGA), and IMPACT-III Questionnaire [ Time Frame: PCDAI, PGA: Week -1 to EOS; IMPACT-II: Week 0, 8 and EOS ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a parent or guardian able to provide written informed consent
  • Be able to provide verbal or written assent depending on age
  • Age 6 to 16 years
  • Have confirmed diagnosis of Crohn's Disease at study time of study entry based on radiologic, endoscopic, or histologic evaluations
  • Have a PCDAI score >/= 30 points
  • Have a negative serum pregnancy test within 7 days prior to receiving the first dose of sargramostim in female patients who, in the opinion of the investigator, are sexually active and of childbearing potential
  • Be able to self-inject sargramostim or have a designee who can do so
  • Available documentations of weight from 4 to 6 months prior to study entry

Exclusion Criteria:

  • Existing colostomy or ileostomy
  • Immediate need of GI surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage
  • GI surgery within 3 month prior to receiving the first dose of sargramostim
  • Symptoms of bowel obstruction or confirmed evidence of a clinically significant stricture within the last 6 month that has not been surgically corrected
  • Use of any of the following medications within 4 weeks prior to receiving the first dose of study drug: 6 mercaptopurine, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, or thalidomide
  • Use of licensed/registered and/or experimental anti-tumor necrosis factor (TNF) therapy such as infliximab or adalimumab within 8 weeks prior to first dose of sargramostim
  • Use of any investigational drug within 4 weeks or 5 half-lives (whichever is greater) prior to receiving the first dose of sargramostim
  • Concurrent use of corticosteroid therapy for Crohn's Disease, which exceeds a dose of 60 mg/day (or equivalent) of prednisone
  • Inability to comply with protocol requirements or provide informed consent
  • Presence of clinically important comorbid condition(s) unrelated to Crohn's Disease
  • Prior use of recombinant human GM-CSF (sargramostim or molgramostim) or granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim)
  • Current use of nutritional therapy (i.e., tube feeding or elemental/polymeric diet) which provides > 50% of daily caloric intake

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00206661

Layout table for location information
United States, California
San Francisco, California, United States, 94117
United States, Georgia
Atlanta, Georgia, United States, 30342
United States, Louisiana
New Orleans, Louisiana, United States, 70118-5799
United States, Massachusetts
Boston, Massachusetts, United States, 02114-2696
United States, New Jersey
Morristown, New Jersey, United States, 07962-1956
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19104-4399
United States, Texas
Houston, Texas, United States, 77030
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company
Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT00206661    
Other Study ID Numbers: 308001
Novel 6
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: December 4, 2013
Last Verified: December 2013
Keywords provided by Sanofi ( Genzyme, a Sanofi Company ):
Crohn Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents